文献速递血管炎

免疫检查点抑制剂诱发的大血管炎:一项欧洲多中心研究的临床特征与管理

Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该欧洲多中心回顾性研究纳入2018年3月至2024年8月期间接受免疫检查点抑制剂(ICI)治疗后发生大血管炎(LVV)的27例成人患者,并与匹配的原发性LVV对照比较。ICI诱发LVV中位诊断时间为3个月,30%接受伊匹木单抗-纳武利尤单抗联合治疗者均在6个月内发生LVV,15%出现视力丧失;中位随访12个月后74%达到持续缓解,33%死亡且主要死于癌症。

要点

  • ICI诱发LVV为少见、早发的免疫相关不良事件,联合ICI治疗者均在6个月内发生。
  • PET扫描诊断和大血管受累在ICI诱发LVV中较匹配的原发性LVV对照更常见。
  • 中位随访12个月后74%达到持续缓解,33%死亡且8例死于癌症。

核心结论

  • ICI诱发LVV是一种少见的早发性免疫相关不良事件。
  • 继续使用ICI可能影响LVV结局,但癌症进展仍是主要死亡原因。
  • 需要前瞻性研究以更好地平衡治疗策略。

研究设计与样本

  • 回顾性、欧洲多中心研究,纳入2018年3月至2024年8月期间接受ICI治疗后发生LVV的成人患者27例,并与匹配的原发性LVV对照比较。
  • LVV通过组织学和/或形态学定义。
  • 患者中位年龄68岁(四分位距61-74岁)。

主要发现

  • 5例(19%)有风湿性多肌痛或巨细胞动脉炎病史。
  • 从ICI启动至LVV诊断的中位时间为3个月(四分位距2-17个月)。
  • 8例(30%)接受伊匹木单抗-纳武利尤单抗联合治疗,均在6个月内发生LVV。
  • 大多数临床特征与匹配对照相似,但PET扫描诊断和大血管受累在ICI诱发LVV中更常见。
  • 4例(15%)出现视力丧失。

关键数值与推荐

  • 管理包括19例(70%)停用ICI并给予糖皮质激素。
  • 中位随访12个月(四分位距5-20个月)后,20例(74%)达到持续缓解。
  • 继续ICI的9例中3例(33%)发生LVV复发或治疗失败,停用ICI的18例中4例(22%)发生LVV复发或治疗失败。
  • 末次随访时9例(33%)死亡,主要死于癌症(n=8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but frequently cause immune-related adverse events (IrAEs). ICI-induced large vessel vasculitis (LVV) is a rare IrAE, with limited available data. We aimed to describe and compare clinical characteristics and evolution of ICI-induced LVV to primary LVV. METHODS: This retrospective, multicentre European study included adult patients who developed LVV after ICI therapy between March 2018 and August 2024. Patients were compared with matched controls with primary LVV. LVV was defined histologically and/or morphologically. RESULTS: Twenty-seven patients were included [median (interquartile range) age 68 (61-74) years]. Five (19%) had a history of polymyalgia rheumatica or GCA. Median time from ICIs initiation to LVV diagnosis was 3 (2-17) months. Eight patients (30%) received ipilimumab-nivolumab combination therapy, all of whom developed LVV within 6 months. Most clinical features were similar to matched controls, however PET scan diagnosis and large-vessel involvement were more common in ICI-induced LVV. Visual loss occurred in 4 (15%) patients. Management included discontinuation of ICIs in 19 (70%) patients and administration of glucocorticoids. After a median follow-up of 12 (5-20) months, 20 (74%) achieved sustained remission. Relapse or treatment failure of LVV occurred in 3/9 (33%) patients who continued ICIs and 4/18 (22%) who discontinued them. By last follow-up, 9 (33%) patients had died, mainly from cancer (n = 8). CONCLUSION: ICI-induced LVV is a rare, early-onset IrAE. Although continuation of ICIs may affect LVV outcomes, cancer progression remains the primary cause of mortality. Prospective studies are warranted to better balance therapeutic approaches.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cottu A, Delaval L, Forestier A, et al. Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study. Rheumatology (Oxford). 2025. PMID: 40139729. doi:10.1093/rheumatology/keaf172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。